Updates are available Correction dated 2024-05-13
Click to view Correction: https://doi.org/10.1038/s44220-024-00263-9
-
Authors
Dijkstra, Eva S. A. http://orcid.org/0000-0002-4679-8674
Frandsen, Summer B.
van Dijk, Hanneke
Duecker, Felix http://orcid.org/0000-0003-0991-9745
Taylor, Joseph J. http://orcid.org/0000-0002-9185-0427
Sack, Alexander T. http://orcid.org/0000-0002-1471-0885
Arns, Martijn http://orcid.org/0000-0002-0610-7613
Siddiqi, Shan H. http://orcid.org/0000-0002-0967-9289
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (K23MH129829, R01MH113929, R21MH12671, R21AA030372, K23MH121657 (PI), R01MH113929 (Co-I))
Brain and Behavior Research Foundation Young Investigator Grant
- License Information
-
More Information
Article History
Received: 5 October 2023
Accepted: 27 March 2024
First Online: 26 April 2024
Change Date: 13 May 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s44220-024-00263-9
Competing interests
: E.S.A.D. is director and owner of Neurowave. A.T.S. is Chief Scientific Advisor of PlatoScience and Alphasys, CEO of Neurowear Medical B.V., received equipment support from MagVenture, Deymed and MagStim Company, and is Scientific Director of the International Clinical TMS Certification Course (). M.A. holds equity/stock in neurocare and Sama Therapeutics, served as consultant to Synaeda, Sama Therapeutics and Roche and is named inventor on patents and intellectual property but receives no royalties. Brainclinics Foundation received equipment support from MagVenture and Deymed. S.H.S. is a scientific consultant for Magnus Medical, is a clinical consultant for Acacia Mental Health, Kaizen Brain Center and Boston Precision Neurotherapeutics, and has received investigator-initiated research funding from Neuronetics and Brainsway. S.H.S. has served as a speaker for Brainsway and PsychU.org (unbranded, sponsored by Otsuka). S.H.S. owns intellectual property involving the use of functional connectivity to target TMS. The other authors declare no competing interests.
